Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04887948 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 570
- Enrollment target
NCT04887948 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 570 participants.
The verdict
NCT04887948, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 570 participants
- Enrollment target
Study Summary
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
Interventions
- OTHER Saline
- BIOLOGICAL BNT162b2
- BIOLOGICAL 20-valent pneumococcal conjugate vaccine (20vPnC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 570 participants |
| Start Date | 2021-05-20 |
| Est. Completion | 2021-12-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04887948
The ClinicalTrials.gov registry entry for NCT04887948 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 570 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline is the first listed.
NCT04887948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04887948 about?
NCT04887948 is a clinical study titled "Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2". Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
What is the current status of trial NCT04887948?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 570 participants. The study started on 2021-05-20. Estimated completion is 2021-12-08.
What interventions are being tested in trial NCT04887948?
The interventions under investigation include: Saline (OTHER), BNT162b2 (BIOLOGICAL), 20-valent pneumococcal conjugate vaccine (20vPnC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04887948?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.